Creative Biolabs

Targeting Delivery for Artificial Cell

Artificial cells (e.g., biomimetic nanoparticles, microencapsulated cells, and synthetic carriers) represent the highest form of targeted delivery. Mimicking natural cell structure and function, they surpass traditional drug carriers by achieving immune escape, long-term circulation, and complex therapeutic integration. Creative Biolabs provides targeted delivery technology development services, focusing on biomimetic engineering and multifunctional assembly to help your innovative therapies achieve in vivo performance comparable to natural cells.

Click Here to View more about our Service

What is Targeted Delivery?

In the field of artificial cells, "targeted delivery" is the core design for achieving complex biological functions. It refers to:

Biomimetic Camouflage and Immune Escape: The carrier surface is modified with natural cell membrane components (such as erythrocyte membranes) to "camouflage" itself, achieving long-term immune escape and ultra-long in vivo circulation.

Multifunctional Integration: Synergistically encapsulating therapeutic payloads, diagnostic probes, and targeting ligands within a single biomimetic structure to achieve an organic integration of diagnosis and treatment (Theranostics).

Complex Environmental Response: Designing artificial cell structures capable of responding to two or more in vivo signals (such as hypoxia, pH changes, specific enzymes, or magnetic fields for carriers like PLGA-Fe3O4) for multifunctional triggering and precise release.

Schematic representation of types and sources of cell-derived biomimetic nano-drug delivery systems. (OA Literature)Fig.1 Types and sources of cell-derived biomimetic nano-drug delivery systems.1

Applications for Artificial Cells

Theranostics

Construction of biomimetic carriers integrating therapeutic drugs, diagnostic contrast agents, and targeting ligands to achieve real-time monitoring of drug delivery, precise diagnosis, and targeted treatment.

Blood Alternatives & Antidotes

Development of biomimetic red blood cells (for oxygen delivery) or biomimetic platelets (for hemostasis and targeted delivery), as well as microencapsulation systems for clearing toxins or pathogens from the body.

Complex Gene Editing & Cell Engineering

Construction of artificial cells with controllable release of gene-editing tools for in vitro cell engineering or in vivo cell reprogramming.

Immune Regulation and Inflammation Therapy

Delivery of artificial or microencapsulated cells with immunosuppressive functions for long-term, stable regulation of autoimmune diseases.

Delivery Challenges of Artificial Cells

The transition of artificial cell technology to clinical reality faces several key challenges:

What We Can Offer

We offer professional targeted delivery technologies, focusing on solving the challenges of biomimetic engineering, stability, and complex functional integration in the field of artificial cells:

Biomimetic Membrane Technology Platform

rane, platelet membrane) extraction and encapsulation technologies for constructing biomimetic nanoparticles with high immune escape and long circulation time.

Multifunctional Carrier Assembly

Focusing on the design and preparation of multilayer liposomes, composite microcapsules, or colloidal crystals to achieve synergistic integration of therapy, diagnostics, and targeted ligands.

High-Stability Microencapsulation Technology

Utilizing our proprietary Microfluidic Biofabrication Platform to precisely control the size, wall thickness, and permeability of artificial cells, achieving the monodisperse (uniform) structures and long-term stability essential for clinical success. This directly addresses the polydispersity issues found in traditional methods.

In vitro and In vivo Functional Validation

Providing professional immune escape testing, in vivo survival time analysis, and in vivo validation services for integrated diagnostic and therapeutic functions (such as imaging and release).

Why Choose Us?

Precision Manufacturing Edge

Our proprietary microfluidic biofabrication Platform guarantees the ultra-uniform size and stability (monodispersity) necessary for clinical translation, overcoming the key manufacturing bottleneck of traditional methods.

Multi-Stimuli Expertise

Deep expertise in developing carriers that respond to diverse triggers, including light, pH, enzymes, and specialized external fields (like magnetic hyperthermia using carriers such as PLGA-Fe3O4).

Translational Focus

We provide comprehensive validation services covering immune evasion, in vivo pharmacokinetics, and functional integration to accelerate your therapeutic pipeline from concept to clinic.

Unmatched IP Library

Access to an exclusive portfolio of membrane and polymer formulations tested for maximum biocompatibility and payload versatility.

Workflow

Service workflow at Creative Biolabs. (Creative Biolabs Original)

Ready to elevate your therapy to the next generation of targeted medicine? Contact our R&D team today to discover how our precision engineering can redefine your delivery system's performance and stability.

Reference

  1. Witika, Bwalya A., et al. "Nano-biomimetic drug delivery vehicles: potential approaches for COVID-19 treatment." Molecules 25.24 (2020): 5952. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/molecules25245952
Our services are For Research Use Only. We do not provide services to individuals.
Online Inquiry

Customer Review

Creatibe Biolabs' custom LNP was the only solution that successfully delivered our CRISPR-Cas9 payload across the blood-brain barrier with high efficiency and low toxicity.”

Dr. Evelyn Reed

Postdoctoral Researcher, Leading University

Our siRNA candidate was failing due to off-target toxicity, but Creatibe Biolabs' team rapidly redesigned our LNP using their modular platform, rescuing our preclinical program.”

Ben Carter

Project Manager

Achieving cytosolic delivery of our protein degrader with Creatibe Biolabs' exosome platform was the key to unlocking our candidate's full therapeutic potential.”

Dr. Kenji Tanaka

Principal Scientist, Large Pharma Corp

Our oncology drug's efficacy was limited by poor tumor accumulation. Creatibe Biolabs' peptide-conjugated liposomes provided the precise targeting we needed, dramatically increasing the drug's therapeutic index.”

Dr. Clara Schmidt

Senior Scientist, Oncology Innovations Inc.

We required a delivery system that would only release its payload in the tumor's acidic microenvironment. Creatibe Biolabs' pH-responsive liposomes performed flawlessly, minimizing systemic exposure.”

David Chen

Formulation Scientist

Outstanding expertise in antibody engineering.The team's attention to detail and innovative approaches have sianificantly accelerated our development timeline.

Sarah L.

Senior Research Scientist

Contact us for more information Get free consultations
ad